MarketMoodz
MRNA — Moderna, Inc.
Is MRNA overbought or oversold? Here is the current MarketMoodz read.
Moderna, Inc. (MRNA) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Biotechnology) last closed at $79.76. The rating moved from Overbought to Neutral on July 3, 2026 and has changed 32 times in the last 90 days.
- Public ratingNeutral (as of July 5, 2026)
- Last close$79.76
- Rating changesRating changed 32 times in the last 90 days
- Last changeMoved from Overbought to Neutral on July 3, 2026
- SectorHealthcare
- IndustryBiotechnology
Latest MarketMoodz coverage
- Cramer: Moderna’s Pipeline Could Re-rate Its Stock2026-07-01
- Apple’s price-hike signal could move the Nasdaq session2026-06-17
- FDA Panel to Review Moderna’s mRNA Flu Shot for Adults2026-06-17
- Moderna Tightens Commercial Focus as Pipeline Advances2026-06-16
- Moderna Posts 5-Year Melanoma Results; CEPI Ebola Deal, Stock Dips2026-06-01
See today's live rating, score and targets
Members see the live hourly rating for MRNA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.